体外成熟
保持生育能力
男科
不育
辅助生殖技术
医学
生育率
卵泡期
妇科
卵母细胞
怀孕
生物
胚胎
内科学
人口
细胞生物学
环境卫生
遗传学
作者
Ri‐Cheng Chian,Jianhua Li,Jin‐Ho Lim,Hiroaki Yoshida
摘要
Abstract Background Thousands of healthy babies are born from in vitro maturation (IVM) procedures, but the rate of efficiency differs with the source of immature oocytes obtained. Recently, there are different IVM protocols proposed for infertility treatment and fertility preservation. Methods Based on the literature, the clinical application for IVM of immature oocytes was summarized. Main findings (Results) Immature oocytes may be retrieved from women after priming with or without the use of follicular stimulation hormone (FSH), human chorionic gonadotrophin (hCG) or a combination of both FSH and hCG. Successful pregnancy rates with IVM technology seem to be correlated with the number of immature oocytes obtained. With the source and culture course of immature oocytes, there are various IVM protocols. IVM of immature oocytes is profoundly affected by the culture conditions, but no breakthrough has been made by improving the IVM medium itself. Thus, the clinical application of IVM technology continues to evolve. Conclusion IVM technology is a useful technique for infertile women and fertility preservation. Mild stimulation IVF combined with IVM of immature oocytes is a viable alternative to the conventional stimulation IVF cycle treatment as it may prove to be an optimal first‐line treatment approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI